AbbVie announces results from single-arm Phase 2 LUMINOSITY trial

AbbVie announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin in patients with c-Met protein overexpression, epidermal growth factor receptor wild type, advanced/metastatic nonsquamous non-small cell lung cancer, or NSCLC. The results demonstrated a compelling overall response rate per independent central review, or ICR, of 35% and 23% across c-Met High and c-Met Intermediate patients respectively. In addition, other endpoints demonstrated meaningful clinical outcomes including median duration of response per ICR of 9 months and 7.2 months and a median overall survival of 14.6 months and 14.2 months across c-Met High and c-Met Intermediate patients respectively. The safety profile of Teliso-V was consistent with previous findings and no new safety concerns were identified. Approximately 85% of lung cancers are classified as NSCLCand despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths in both men and women throughout the world. C-Met protein overexpression is found in approximately 25% of advanced EGFR wild type NSCLC patients3 and is associated with a poor prognosis for these patients.4,5,6 Teliso-V, an investigational ADC, is being studied in this patient population who have very limited treatment options and where there are currently no approved therapies.